Equine Viral Arteritis: Comprehensive Guide For Horse Owners

Equine viral arteritis (EVA) represents a significant health concern for equids, manifesting as a respiratory, systemic, and reproductive disorder caused by the equine arteritis virus (EAV). This pathogen targets blood vessel linings, leading to inflammation known as vasculitis, which can result in a range of clinical outcomes from mild fever to severe complications like abortion or neonatal mortality.

The Nature and Global Impact of EVA

EVA occurs worldwide, with serological evidence of exposure in many equine populations, though clinical outbreaks remain relatively infrequent. The virus belongs to the Arteriviridae family and primarily affects horses, donkeys, and other equids. Its economic importance stems from disruptions in breeding programs, potential abortion storms in mares, and the establishment of long-term carriers among stallions, who shed the virus in semen.

Historical outbreaks, such as the notable 1984 incident in Kentucky involving over 80 Thoroughbreds, underscore the potential for rapid spread in dense populations like racetracks or studs. Despite its presence globally, stringent management practices have kept it under control in many regions.

How EVA Spreads Among Horses

Transmission occurs through multiple routes, making biosecurity paramount. Primary modes include:

• Respiratory spread: Inhalation of aerosolized viral particles during close contact, such as in stables or during transport.
• Venereal transmission: Direct contact via breeding or artificial insemination with infected semen, where stallions serve as key reservoirs.
• Fomites: Contaminated equipment, tack, feed buckets, or handlers’ hands facilitate indirect spread.

The incubation period typically ranges from 3 to 14 days, with peak shedding in respiratory secretions around days 5-8 post-infection. Carrier stallions can perpetuate the virus indefinitely without symptoms, emphasizing the need for semen testing in breeding programs.

Clinical Manifestations in Different Horse Groups

Symptom severity varies by age, sex, immune status, and strain virulence. Many infections are subclinical, with over 90% of adult horses showing no signs.

Signs in Adult Horses

Common presentations include:

• Fever (up to 106°F/41°C)
• Lethargy and anorexia
• Nasal discharge (serous to mucopurulent)
• Conjunctivitis with lacrimation and edema around eyes
• Limb and ventral edema due to vasculitis
• Stiff gait or ataxia
• In stallions: Scrotal swelling, preputial edema, and temporary infertility

These signs usually resolve within 1-2 weeks as vascular lesions heal, peaking around day 10 post-infection.

Effects on Pregnant Mares and Foals

Pregnant mares face high abortion risk (50-70% in outbreaks), often late-term due to placental vasculitis and fetal infection affecting organs like lungs and liver. Foals under 3 months suffer interstitial pneumonia, leading to respiratory distress and high mortality rates, sometimes exceeding 50% without intervention.

Pathophysiology: Why EVA Causes Damage

Upon entry, EAV replicates in monocytes and endothelial cells, disseminating via bloodstream. It induces proinflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α), causing endothelial swelling, medial necrosis, edema, and hemorrhage in vessels. Recovery involves immune clearance, though some stallions harbor virus in ampulla of vas deferens.

Accurate Diagnosis of EVA

Definitive diagnosis combines clinical signs with lab confirmation:

• Virus detection: RT-PCR on nasal swabs, blood, semen, or tissues; virus isolation in cell culture.
• Antigen detection: Immunohistochemistry on biopsies.
• Serology: Paired sera for SN or VN antibodies; IgM indicates recent infection.

Semen testing is critical for stallions pre-breeding. False negatives occur early, so repeat testing may be needed.

Management and Supportive Therapy

No antiviral drugs exist; focus is supportive care tailored to severity.

• For adults: Antipyretics (flunixin meglumine), anti-inflammatories, diuretics (furosemide) for edema, stall rest.
• For foals: IV fluids, oxygen, antibiotics against secondary bacteria, nutritional support.
• Stallions: Monitor fertility; castration eliminates carrier status if breeding is not essential.

Most horses recover fully without intervention, but severe cases benefit from nursing.

Vaccination: Key to Prevention

Vaccines mitigate clinical disease and carrier formation:

• Modified-live (North America): Effective against respiratory signs, abortion, and stallion carriage; annual boosters.
• Inactivated (Europe): Safer for pregnant mares.

Vaccinate weanlings, breeding stock, and before shows. Withhold 3 weeks pre-breeding for live vaccines.

Biosecurity and Outbreak Control

Prevent spread via:

• Quarantine new arrivals (3 weeks).
• Semen screening and EVA-negative certification.
• Disinfect fomites (virus inactivated by detergents, bleach).
• Separate naive from exposed horses.

During outbreaks, halt breeding and isolate cases.

Frequently Asked Questions (FAQs)

Can EVA be fatal?

Rarely in adults, but yes in young foals due to pneumonia.

How long do carriers shed virus?

Indefinitely until cleared naturally (years) or via management.

Is EVA reportable?

Yes in some countries; check local regulations.

Can vaccinated mares still abort?

Risk greatly reduced, but not zero.

What disinfectants work?

1:10 bleach, iodophors, quaternary ammoniums.

Long-Term Implications for Horse Owners

EVA underscores the value of proactive health management. Regular serology, vaccination compliance, and breeding hygiene safeguard herds. While self-limiting in most cases, its reproductive impact demands vigilance. Consult veterinarians for tailored protocols, ensuring equine populations thrive amid potential threats.